← FDA DRUG APPROVALS

FDA ANDA · ANDA090324

CARBIDOPA AND LEVODOPA

Sponsor: PHARMOBEDIENT

APPLICATION
ANDA090324
TYPE
ANDA
ORIGINAL APPROVAL
2009-09-28
LATEST ACTION
2021-02-02
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued, Prescription

Products

CARBIDOPA AND LEVODOPADiscontinued
CARBIDOPA 25MG, LEVODOPA 250MG · TABLET · ORAL
CARBIDOPA AND LEVODOPADiscontinued
CARBIDOPA 10MG, LEVODOPA 100MG · TABLET · ORAL
CARBIDOPA AND LEVODOPAPrescription
CARBIDOPA 25MG, LEVODOPA 100MG · TABLET · ORAL

Approval history

2021-02-02Labeling · Supplement 8 · standardAP
2015-11-19Labeling · Supplement 5 · standardAP
2015-11-19Labeling · Supplement 4 · standardAP
2009-09-28OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →